Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02277522 · ClinicalTrials.gov registry record · Early Phase 1
CD19 Redirected Autologous T Cells for Hodgkin Lymphoma
A Early Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
NCT02277522: Clinical Trial Early Phase 1 study, sponsored by University of Pennsylvania.
NCT02277522 is a Early Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02277522, a Early Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Pilot open-label study to estimate the feasibility, safety and efficacy of intravenously administered, RNA electroporated autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART19) in Hodgkin Lymphoma (HL) patients.
Interventions
- BIOLOGICAL RNA anti-CD19 CAR T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2014-10 |
| Est. Completion | 2017-06-27 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02277522
The ClinicalTrials.gov registry entry for NCT02277522 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RNA anti-CD19 CAR T cells is the first listed.
NCT02277522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02277522 about?
NCT02277522 is a clinical study titled "CD19 Redirected Autologous T Cells for Hodgkin Lymphoma". Pilot open-label study to estimate the feasibility, safety and efficacy of intravenously administered, RNA electroporated autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART19) in Hodgkin Lymphoma (...
What is the current status of trial NCT02277522?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2014-10. Estimated completion is 2017-06-27.
What interventions are being tested in trial NCT02277522?
The interventions under investigation include: RNA anti-CD19 CAR T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02277522?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.